MK2461

Merck Sharp & Dohme LLC · Phase 1 active Small molecule

At a glance

Generic name	MK2461
Sponsor	Merck Sharp & Dohme LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED) (PHASE1, PHASE2)
MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MK2461 CI brief — competitive landscape report
MK2461 updates RSS · CI watch RSS
Merck Sharp & Dohme LLC portfolio CI